Biotechnology company Kallyope raised $ 21 million in a funding round led by Microsoft founder Bill Gates to develop technologies based on the gut - brain axis . The backing was an extension to the firm ’s initial B funding round which had already raised $ 66 m . The company developed a platform based on analysis of the bi - directional communication between the gut and the brain and announced it had expanded its research to a series of programmes aimed at studying disorders of the metabolic , central nervous and gastrointestinal systems .
Biotechnology company Kallyope raised $21m in a funding round led by Microsoft founder Bill Gates to develop therapies based on the gut-brain axis. The backing was an extension to the firm’s series B funding round which had already raised $66m. The company developed a platform centred on analysis of the bi-directional communication between the gut and the brain and said it had expanded its research to a series of programmes aimed at studying disorders of the metabolic, central nervous and gastrointestinal systems.